Cargando…
Ethics of randomised controlled trials – not yet time to give up on equipoise
In this commentary on Fries and Krishnan's argument that 'design bias' undermines the status of equipoise as the ethical justification for randomised controlled trials, it is argued that their argument is analogous to Bayesian arguments for the use of informative priors in trial desig...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064870/ https://www.ncbi.nlm.nih.gov/pubmed/15535836 http://dx.doi.org/10.1186/ar1442 |
_version_ | 1782123314124161024 |
---|---|
author | Ashcroft, Richard E |
author_facet | Ashcroft, Richard E |
author_sort | Ashcroft, Richard E |
collection | PubMed |
description | In this commentary on Fries and Krishnan's argument that 'design bias' undermines the status of equipoise as the ethical justification for randomised controlled trials, it is argued that their argument is analogous to Bayesian arguments for the use of informative priors in trial design, but that this does not undermine the importance of equipoise. In particular, mismatches between the outcomes of interest to industrial sponsors of research and outcomes of interest to patients and clinicians ensure that in many cases industry-sponsored trials can fail to reflect the reasonable equipoise of working clinicians. |
format | Text |
id | pubmed-1064870 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-10648702005-03-12 Ethics of randomised controlled trials – not yet time to give up on equipoise Ashcroft, Richard E Arthritis Res Ther Commentary In this commentary on Fries and Krishnan's argument that 'design bias' undermines the status of equipoise as the ethical justification for randomised controlled trials, it is argued that their argument is analogous to Bayesian arguments for the use of informative priors in trial design, but that this does not undermine the importance of equipoise. In particular, mismatches between the outcomes of interest to industrial sponsors of research and outcomes of interest to patients and clinicians ensure that in many cases industry-sponsored trials can fail to reflect the reasonable equipoise of working clinicians. BioMed Central 2004 2004-09-14 /pmc/articles/PMC1064870/ /pubmed/15535836 http://dx.doi.org/10.1186/ar1442 Text en Copyright © 2004 BioMed Central Ltd |
spellingShingle | Commentary Ashcroft, Richard E Ethics of randomised controlled trials – not yet time to give up on equipoise |
title | Ethics of randomised controlled trials – not yet time to give up on equipoise |
title_full | Ethics of randomised controlled trials – not yet time to give up on equipoise |
title_fullStr | Ethics of randomised controlled trials – not yet time to give up on equipoise |
title_full_unstemmed | Ethics of randomised controlled trials – not yet time to give up on equipoise |
title_short | Ethics of randomised controlled trials – not yet time to give up on equipoise |
title_sort | ethics of randomised controlled trials – not yet time to give up on equipoise |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1064870/ https://www.ncbi.nlm.nih.gov/pubmed/15535836 http://dx.doi.org/10.1186/ar1442 |
work_keys_str_mv | AT ashcroftricharde ethicsofrandomisedcontrolledtrialsnotyettimetogiveuponequipoise |